• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169544 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

' b8 S* o2 R4 z% I: _可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  * q) Z  R! N8 H& q3 p
: ~$ f( T* d  h- F. @. {) i& Z" j
, }6 t$ ?! I: ?: U  a/ k& V
Sub-category:
& y5 s: R; q2 u- ^Molecular Targets ' ^% X$ y! f& }( W1 g/ i8 A8 B1 z8 l  s

# A" k/ l& X$ _  V8 Z8 v! S3 B) `7 h
Category:8 `- U4 P. G; z. X" P" u
Tumor Biology 7 n+ E6 Q& S: {: T% C% A. c( [
9 H( }) |7 O) {

! L- ]  p. z$ ]5 O" `Meeting:, i5 Z$ O& M( E* W5 H
2011 ASCO Annual Meeting ; I7 U% {% q/ e+ g  @

9 c& ^& c, Z& j4 |7 N" m. L5 p1 [4 s) q
Session Type and Session Title:; a* A) a& P9 J; a( J/ \- `
Poster Discussion Session, Tumor Biology 2 D; P, m4 K6 c  j7 R
$ J) Z* b. r: m$ z' S

$ S6 W2 e7 m! z- @+ A, FAbstract No:
/ ]/ H1 Z, x# i+ ?# p6 z10517
1 h0 r. J' V5 e; C% e% d0 c$ u4 f% p$ a9 s
1 Z+ \: s( S! W; r0 w6 K, i
Citation:
4 e: c% K" W( x0 V& G9 }J Clin Oncol 29: 2011 (suppl; abstr 10517) / Q( p# j8 L# n( h- P3 _8 L

. b1 d+ ?( x4 O" K* `* e
' g* y4 Z, }% c0 G7 d- k6 ZAuthor(s):
+ F6 g+ A% p" T* g0 h' jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ( W" ?. j' W; D- s* y% V2 I' ?
0 `. X' H9 ]/ |) ^0 J

; o# k1 k- W5 a
/ I# S0 _1 W; i$ i! yAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# n0 [8 f% ^% |" b+ M5 n5 \
8 z9 z1 M! a, Z3 T% D/ PAbstract Disclosures
7 c0 q% G( l  S& [5 n0 v
6 V' a' }' [8 E+ {4 WAbstract:
4 n1 |9 a+ u" [& u1 w+ c) B5 f) M4 }5 v) E! ?  n
8 ]6 j0 j* y% K( B1 I5 r
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.% v% A5 M$ Y1 Z

! x5 [9 I- X: b' T7 j3 b# ~8 ? 3 R5 h: l$ C; ~
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 9 m* O) o- U9 |8 m6 z8 R9 |3 ?2 {1 N
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

, V. @  u, W; M/ T" }化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 + N2 i) D: K+ d& P$ U. D5 `6 x. W- Z
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。& l' N1 I3 ^: L# c
ALK一个指标医院要900多 ...
  p/ z- G: ^9 u7 Z
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 T4 r0 P9 A" f0 l. b( c* ~
. c8 x8 U6 u3 Z8 w+ n
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表